

## THE DISTILLERY

## This week in therapeutics

| Indication      | Target/marker/pathway   | Summary  | Licensing status                                     | Publication and contact<br>information  |
|-----------------|---|--|--|---|
| Cancer          |   |  |  |   |
| Prostate cancer | Glutathione peroxidase<br>3 plasma (GPX3); tumor<br>protein p53 inducible<br>protein 3 (TP53I3; PIG3) | <i>In vitro</i> studies suggest increasing the activity<br>of GPX3 and PIG3 could help treat prostate<br>cancer. In human prostate cancer cell lines<br>and immortalized prostate epithelial cells, the<br>tumor suppressor GPX3 colocalized with PIG3.<br>In the same cells, anti-GPX3 and anti-PIG3<br>small interfering RNA decreased both reactive<br>oxygen species (ROS) and UV-induced cell death<br>compared with scrambled siRNA control. Next<br>steps include additional studies of the effects of<br>increasing PIG3 levels. | Findings unpatented;<br>unavailable for<br>licensing | Wang, H. <i>et al. J. Biol. Chem.</i> ;<br>published online March 29, 2012;<br>doi:10.1074/jbc.M111.322636<br><b>Contact:</b> Yan P. Yu, University of<br>Pittsburgh School of Medicine,<br>Pittsburgh, Pa.<br>e-mail:<br>ypyu@pitt.edu |
|                 |   | <i>SciBX</i> 5(17); doi:10.1038/scibx.2012.438   |  |   |

Published online April 26, 2012